Paratek Pharmaceuticals, Inc.

NasdaqGM:PRTK 주식 리포트

시가총액: US$127.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Paratek Pharmaceuticals 향후 성장

Future 기준 점검 4/6

현재 Paratek Pharmaceuticals 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

핵심 정보

73.2%

이익 성장률

72.86%

EPS 성장률

Pharmaceuticals 이익 성장14.5%
매출 성장률13.8%
향후 자기자본이익률n/a
애널리스트 커버리지

Low

마지막 업데이트07 Aug 2023

최근 향후 성장 업데이트

Recent updates

분석 기사 • Apr 17

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) shares have had a really impressive month, gaining 77% after a shaky...
Seeking Alpha • Aug 24

Paratek Pharmaceuticals: Patience Is Wearing Thin

Summary Today, we put Paratek Pharmaceuticals in the spotlight for the first time since the early fall of last year. Paratek is advancing its flagship product NUZYRA nicely, but shareholders have not been rewarded to this point in time even as the shares have strong analyst support. What lies ahead for Paratek? An investment analysis follows in the paragraphs below. If you must speak ill of another, do not speak it, write it in the sand near the water's edge. ― Napoleon Hill Today, we are circling back on Paratek Pharmaceuticals (PRTK) for the first time since we posted this piece on this small antibiotic concern back in October of last year. Even as the company has demonstrated solid revenue growth, shareholders have not been rewarded in this name over the past year and patience is starting to wear thin. We update our investment thesis around Paratek Pharmaceuticals via the analysis below. Seeking Alpha Company Overview Paratek Pharmaceuticals is a Boston based antibiotic concern. The company's primary asset is NUZYRA. This is a once-daily oral and intravenous broad-spectrum antibiotic approved for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. The stock sells for around $2.75 a share and sports an approximate market cap of just under $150 million. August Company Presentation The company has some earlier stage candidates in its pipeline. None of them of note to this analysis given they are early in development. The company is advancing NUZYRA in Phase 2 development for Non-Tuberculous Mycobacteria or NTM for which it has Orphan Drug and Fast Track designations from the FDA. August Company Presentation Second Quarter Results On August 3rd, the company posted second quarter numbers. Paratek posted a GAAP loss of 33 cents a share, just a tad above the consensus. Net revenue for the second quarter of 2022 was $29.6 million. This compares to $19.6 million in 2Q2021 when excluding the first procurement of NUZYRA under the BARDA contract of $37.9 million (more detail on that contract in the last section of this article). August Company Presentation The $29.6 million in sales for the quarter included $25.1 million of revenues from NUZYRA's core commercial business. This was up from $14.9 million from the same period a year ago. The company also booked $4 million in sales from the BARDA contract and $600,000 in royalty revenue from SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. August Company Presentation Analyst Commentary & Balance Sheet Only three analyst firms have chimed in around Paratek so far in 2022. On February 10th, WBB Securities upgraded the shares to a Strong Buy with a $11 price target as the analyst there believes 'Nuzyra is a critically important antibiotic that has anchored the franchise'. This month BTIG ($30 price target) and H.C. Wainwright ($20 price target) both maintained their Buy ratings on the stock. Just under 10% of the outstanding float is currently held short. Four insiders sold just over $300,000 worth of shares collectively in August. That has been the only insider activity in the equity so far in 2022. The company ended the first half of this year with nearly $70 million in cash and marketable securities on its balance sheet. Management stated within its second quarter earnings press release that: Based upon the company's current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4 million as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even. August Company Presentation Verdict The current analyst consensus has the company losing a bit over 80 cents a share in FY2022 as revenues rise in the mid teens to some $150 million. Projections from three analyst firms that have provided estimates for FY2023 are in wide range both for earnings (A 42 cent a share loss to profits of $1.37 a share) and revenues ($195 million to $315 million).
Seeking Alpha • Aug 03

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Paratek Pharmaceuticals press release (NASDAQ:PRTK): Q2 GAAP EPS of -$0.33 beats by $0.01. Revenue of $29.6M (-48.5% Y/Y) beats by $0.42M. Based upon the company’s current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4M as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even.
Seeking Alpha • Jan 03

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

2021 revenue estimate: $128-139 million; 2022 revenue estimate: $200 million. Revenue estimates for CABP and ABSSSI near $400 million by 2028; NTM could generate even higher sales well into the 2030s. $304 million BARDA contract (2019-2023) provides a pathway to profitability by 4Q2022. Deeply undervalued: enterprise value of $369 million is less than 2X 2022 sales.
Seeking Alpha • Oct 18

The Play On Paratek Pharmaceuticals

Today, we take a quick look back at antibiotic concern Paratek Pharmaceuticals. While I am very underweight the antibiotic space due to the terrible economics there, Paratek has some unique features that make the stock one I own. An analysis and how I am positioned in Paratek Pharmaceuticals follows in the paragraphs below.
Seeking Alpha • Aug 07

Peeking Back In On Paratek Pharmaceuticals

The stock of Paratek Pharmaceuticals has fallen since we last took an in-depth look at this antibiotic company in March. Most of this is due to weakness in the sector. The company continues to make solid progress, and its shares are far below analyst firm price targets. A full and independent investment analysis follows in the paragraphs below.
분석 기사 • Mar 01

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) is possibly approaching a major achievement in its business, so we would...
분석 기사 • Feb 01

Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

A look at the shareholders of Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) can tell us which group is most powerful...

이익 및 매출 성장 예측

NasdaqGM:PRTK - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/20252212-9N/A2
12/31/2024218-1430N/A3
12/31/2023163-46-10N/A2
6/30/2023177-63-23-23N/A
3/31/2023167-66-36-36N/A
12/31/2022160-64-66-66N/A
9/30/2022117-89-66-66N/A
6/30/2022111-86-27-27N/A
3/31/2022139-59-46-46N/A
12/31/2021130-59-49-48N/A
9/30/2021114-52-53-52N/A
6/30/2021104-54-108-107N/A
3/31/202155-87-95-95N/A
12/31/202047-97-104-103N/A
9/30/202040-99-116-115N/A
6/30/202030-111-115-114N/A
3/31/202023-121-129-129N/A
12/31/201917-129-134-134N/A
9/30/201925-124-118-117N/A
6/30/201921-124-110-110N/A
3/31/201919-120-98-98N/A
12/31/201817-112-81-81N/A
9/30/20185-111-85-85N/A
6/30/20185-101-80-80N/A
3/31/201813-89-73-73N/A
12/31/201713-89-80-79N/A
9/30/20178-94-82-80N/A
6/30/20178-96-95-94N/A
3/31/20170-108N/A-101N/A
12/31/20160-112N/A-94N/A
9/30/2016N/A-106N/A-86N/A
6/30/2016N/A-106N/A-78N/A
3/31/2016N/A-91N/A-70N/A
12/31/2015N/A-71N/A-55N/A
9/30/20154-61N/A-49N/A
6/30/20154-42N/A-30N/A
3/31/20154-29N/A-18N/A
12/31/20144-20N/A-19N/A
9/30/20140-12N/A-9N/A
6/30/20141-11N/A-8N/A
3/31/20140-11N/A-8N/A
12/31/20130-11N/A-6N/A
9/30/20131-37N/A-9N/A
6/30/20131-41N/A-11N/A
3/31/20133-45N/A-10N/A
12/31/20123-50N/A-12N/A
9/30/20124-28N/A-12N/A

애널리스트 향후 성장 전망

수입 대 저축률: PRTK 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(2.2%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: PRTK (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: PRTK 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: PRTK 의 수익(연간 13.8%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: PRTK 의 수익(연간 13.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: PRTK의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2023/09/22 01:29
종가2023/09/20 00:00
수익2023/06/30
연간 수익2022/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Paratek Pharmaceuticals, Inc.는 11명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Michael UlzBaird
Jason Matthew GerberryBofA Global Research
Timothy ChiangBTIG